Veru to Participate in Fireside Chat at the Jones Healthcare and Technology Innovation Conference

MIAMI, FL, March 31, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced that Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer of Veru, will participate in a fireside chat at the upcoming Jones Healthcare and Technology Innovation Conference, in Las Vegas, Nevada, on April 9, 2025 at 3:00 pm – 3:20 pm Pacific Daylight Time.

A recording will be accessible one day after the conclusion of the conference on the Company’s website at www.verupharma.com. To attend the fireside chat or conference please email Jones Trading at [e-mail].

About Veru Inc.
Veru is a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases. The Company’s drug development program includes two late-stage novel small molecules, enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator (SARM), is being developed as a next generation drug that makes weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass thereby improving body composition and physical function. Sabizabulin, a microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease.

Obesity Program- enobosarm is a next generation drug that makes weight reduction by GLP-1 RA more tissue selective for fat loss– Phase 2b QUALITY clinical study.
On January 27, 2025, the Company announced positive topline results from its Phase 2b, multicenter, double-blind, placebo-controlled, randomized, dose-finding QUALITY clinical trial to evaluate enobosarm 3mg, enobosarm 6mg, or placebo as a treatment to preserve lean body mass and augment loss of fat in 168 obese or overweight older (>60 years of age) patients receiving semaglutide (Wegovy).

The trial met its prespecified primary endpoint with a statistically significant and a clinically meaningful benefit in the preservation of total lean body mass in all patients receiving enobosarm + semaglutide versus placebo + semaglutide at 16 weeks (71% relative reduction in lean mass loss, p=0.002). The enobosarm 3mg + semaglutide was the best dose with a >99% mean relative reduction in loss of lean mass (p <0.001).